Találati lista | Tudóstér

001-es BibID:	BIBFORM113120
035-os BibID:	(cikkazonosító)101939 (scopus)85151507775
Első szerző:	Salmanton-García, Jon
Cím:	Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies : a report from the EPICOVIDEHA registry / Salmanton-García Jon, Marchesi Francesco, Gomes da Silva Maria, Farina Francesca, Dávila-Valls Julio, Bilgin Yavuz M., Glenthj Andreas, Falces-Romero Iker, Van Doesum Jaap, Labrador Jorge, Buquicchio Caterina, El-Ashwah Shaimaa, Petzer Verena, Van Praet Jens, Schönlein Martin, Dargenio Michelina, Méndez Gustavo-Adolfo, Meers Stef, Itri Federico, Giordano Antonio, Pinczés László Imre, Espigado Ildefonso, Stojanoski Zlate, López-García Alberto, Prezioso Lucia, Jaksic Ozren, Vena Antonio, Fracchiolla Nicola S., González-López Tomás José, Colovic Natasa, Delia Mario, Weinbergerová Barbora, Marchetti Monia, Marques de Almeida Joyce, Finizio Olimpia, Besson Caroline, Biernat Monika M., Valkovic Toni, Lahmer Tobias, Cuccaro Annarosa, Ormazabal-Vélez Irati, Batinic Josip, Fernández Noemí, De Jonge Nick, Tascini Carlo, Anastasopoulou Amalia N., Duléry Rémy, Del Principe Maria Ilaria, Plantefeve Gaëtan, Papa Mario Virgilio, Nucci, Marcio; Jiménez, Moraima; Aujayeb, Avinash; Hernández-Rivas, José-Ángel; Merelli, Maria; Cattaneo, Chiara; Blennow, Ola; Nordlander, Anna; Cabirta, Alba; Varricchio, Gina; Sacchi, Maria Vittoria; Cordoba, Raul; Arellano, Elena; Gräfe, Stefanie K.; Wolf, Dominik, Emarah Ziad, Ammatuna Emanuele, Hersby Ditte Stampe, Martín-Pérez Sonia, Nunes Rodrigues, Raquel Rahimli, Laman, Pagano Livio, Cornely Oliver A., EPICOVIDEHA registry
Dátum:	2023
ISSN:	2589-5370
Megjegyzések:	Background Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. eClinicalMedicine 2023;58: 101939 Published Online 6 April 2023 https://doi.org/10. 1016/j.eclinm.2023. 101939 Articles 2 www.thelancet.com Vol 58 April, 2023 Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan?Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ?1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448?4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619?8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093?0.732) and obesity (aOR 0.105, 95%CI 0.014?0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir.
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Nirmatrelvir SARS-CoV-2 Haematology Malignancy COVID-19
Megjelenés:	eClinicalMedicine. - 58 (2023), p. 1-19. -
További szerzők:	Marchesi, Francesco Gomes Da Silva, Maria Farina, Francesca Dávila-Valls, Julio Bilgin, Yavuz M. Glenthj, Andreas Falces-Romero, Iker van Doesum, Jaap Labrador, Jorge Buquicchio, Caterina El-Ashwah, Shaimaa Petzer, Verena van Praet, Jens Schönlein, Martin Dargenio, Michelina Méndez, Gustavo-Adolfo Meers, Stef Itri, Federico Giordano, Antonio Pinczés László Imre (1990-) (hematológus) Espigado, Ildefonso Stojanoski, Zlate López-García, Alberto Prezioso, Lucia Jaksic, Ozren Vena, Antonio Fracchiolla, Nicola S. González-López, Tomás José Colovic, Natasa Delia, Mario Weinbergerová, Barbora Marchetti, Monia Marques de Almeida, Joyce Finizio, Olimpia Besson, Caroline Biernat, Monika M. Valkovic, Toni Lahmer, Tobias Cuccaro, Annarosa Ormazabal-Vélez, Irati Batinić, Josip Fernández, Noemí de Jonge, Nick Tascini, Carlo Anastasopoulou, Amalia N. Duléry, Rémy Del Principe, Maria Ilaria Plantefeve, Gaëtan Papa, Mario Virgilio Nucci, Marcio Jiménez, Moraima Aujayeb, Avinash Hernández-Rivas, José-Ángel Merelli, Maria Cattaneo, Chiara Blennow, Ola Nordlander, Anna Cabirta, Alba Varricchio, Gina Sacchi, Maria Vittoria Cordoba, Raul Arellano, Elena Gräfe, Stefanie K. Wolf, Dominik Emarah, Ziad Ammatuna, Emanuele Hersby, Ditte Stampe Martín-Pérez, Sonia Nunes Rodrigues, Raquel Rahimli, Laman Pagano, Livio Cornely, Oliver Andreas EPICOVIDEHA registry
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: